Vitamin E administration improves endothelial function in hypercholesterolaemic animals but, generally, has not been found to do so in man. The aim of this study was to determine whether vitamin E administration improves basal or stimulated function of the nitric oxide ([NO) dilator system in patients with hypercholesterolaemia.
INTRODUCTION
In recent years the important contribution of endothelial cell function to cardiovascular health has received increasing recognition. Endothelial dysfunction, expressed as abnormal vascular responses to nitric oxide ([NO) agonists and antagonists or to flow-mediated dilation, has been reported in cigarette smokers and in patients Key words : acetylcholine, antioxidants, brachial artery cannulation, endothelium-derived factors, forearm blood flow, hypercholesterolaemia, monomethyl arginine, vitamin E.
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Correspondence : Dr Daniel J. Green. with essential hypertension, chronic heart failure patients, diabetes and hypercholesterolaemia. These studies have prompted the suggestion that endothelial dysfunction may represent an early manifestation in the process of atherosclerosis [1] .
Studies performed in hypercholesterolaemic animals and man indicate that endothelium-dependent [NOmediated vasodilatation is depressed, although the mechanisms are unclear [2] . Paradoxically, studies in vitro indicate that [NO production is enhanced, rather than impaired, in hypercholesterolaemia and in atherosclerotic vessels. Since the concentrations of reactive oxygen species, such as superoxide anions ([O # − ) and oxidatively modified low-density lipoprotein (LDL), are enhanced in hypercholesterolaemia, and these can inactivate [NO, it has been suggested that the [NO dilator system dysfunction in hypercholesterolaemia may be due to excessive destruction of [NO before its effect on vascular smooth muscle cells [2] . If this is the case, a beneficial effect on endothelial function might be expected from antioxidant strategies, including the administration of antioxidant vitamins.
Some epidemiological studies indicate that plasma vitamin E (α-tocopherol) concentration is inversely correlated with cardiovascular morbidity and mortality, although the evidence remains inconclusive. In addition, some experimental studies and clinical observations [3] [4] [5] [6] [7] [8] suggest that administration of vitamin E can retard the development of atherosclerosis or its complications, although very high doses in rabbits have been harmful [9, 10] . Cardiovascular protection afforded by vitamin E has generally been attributed to an antioxidant effect via decreased production of reactive oxygen species or reduced lipid peroxidation, as demonstrated by Princen et al. [6] for example, but how this is translated into beneficial effects is uncertain. Vitamin E has been reported to inhibit smooth muscle cell proliferation [11] and monocyte adhesion to endothelial cells [12] , and to protect endothelial cells from damage by oxidized LDL, probably by reducing protein kinase C activation [13] . In addition, vitamin E has improved endothelium-dependent [NO dilator function in the cholesterol-fed hypercholesterolaemic rabbit [14, 15] . However, studies in several clinical situations [16] [17] [18] [19] , and a previous study of ours in normolipidaemic subjects [20] , failed to find improvement in endothelial function after vitamin E administration. The purpose of the present study was to examine the effect of vitamin E administration on basal and stimulated function of the [NO dilator system in subjects with hypercholesterolaemia.
METHODS
Subjects were eligible for entry if they had a total serum cholesterol level 5:5 mmol\l and were not receiving cholesterol-lowering therapy. Seven subjects were enrolled : five men and two women, aged 47p3 years. All undertook a screening programme consisting of a medical history and examination, haematological and biochemical profile, including measurement of serum electrolytes, liver function, uric acid, creatine phosphokinase and serum lipids. The following were excluded : cigarette smokers, premenopausal females, those with renal and hepatic impairment, hypertension ( 140\90 mmHg) or diabetes mellitus and those taking vitamin supplements or any medication. The study protocol was approved by the Royal Perth Hospital Ethics Committee and subjects gave their written consent.
Experimental design
The effect of 4 weeks therapy with vitamin E was studied using a placebo-controlled, single-blind design. A randomized crossover protocol was not used due to uncertainty regarding the tissue half-life and consequent washout period of α-tocopherol. Subjects were therefore administered a placebo preparation for 4 weeks, followed by 500 i.u. of α-tocopherol twice daily (R. P. Scherer, Australia) for a further 4 weeks. Each subject undertook two studies of forearm vascular function, performed at the end of the placebo and vitamin E administration periods. All abstained from eating and drinking caffeinated beverages for 6 h before the experimental sessions, which were held at the same time of day. Plasma α-tocopherol concentrations were determined from samples collected at the beginning of each experimental session by a reverse-phase HPLC method after plasma extraction into hexane.
Vascular function protocol
Investigations were conducted in a quiet, temperaturecontrolled laboratory (24.0p0.4 mC) with subjects lying supine and both forearms resting above heart level. A 20-gauge arterial cannula (Arrow, Reading, PA, U.S.A.) was introduced into the brachial artery of the non-dominant arm under local anaesthesia with 2 ml of 1 % lignocaine (Astra Pharmaceuticals, Australia), to transduce pressure and for the infusion of drugs or physiological saline. Forearm blood flow (FBF, ml −" :min −" :100 ml −" forearm) was measured simultaneously in both arms by gallium\indium strain-gauge plethysmography (SG24, Medasonics, Mountain View, CA, U.S.A.). Each wrist cuff was connected to a flow-regulated source of compressed air and the arm cuffs were connected to a rapid inflation device (E20, D. E. Hokanson, Western Australia). Output from the strain gauges passed through an amplifier (SPG 16, Medasonics) and was sampled by an on-line microcomputer at 75 Hz before being displayed on a monitor in real time. A software program co-ordinated the acquisition, storage and display of data as well as inflation and deflation of the arm cuffs, ensuring that blood flow measures were synchronized with cuff inflation during recording periods. Intra-arterial pressure was continuously measured (Transpac, Abbot Laboratories, IL, U.S.A.) throughout the study. Drug infusions were administered using a constant-rate infusion pump (IVAC 770, IVAC Corporation, CA, U.S.A.).
Baseline measurements started at least 25 min after cannulation of the brachial artery, when FBF had stabilized. Blood flow measurements were taken by inflating the wrist cuffs to 220 mmHg, to exclude the hands from the circulation, and by rapidly inflating the upper arm cuffs to 45 mmHg for 10 out of every 15 s throughout the baseline and drug infusion periods. Output from the strain gauges was stored and the average of the last five flow measurements from each period was used for analysis. Between infusions, the cuffs were deflated, allowing at least 15 min for FBF to recover before further baseline measures were recorded.
Drug infusions
All solutions were prepared aseptically from sterile stock solutions or ampoules immediately before brachial artery infusion. Acetylcholine (Miochol ; Johnson & Johnson, Australia) was infused at 10, 20 and 40 µg\min, each for 3 min, to produce a cumulative dose-response curve. This was followed by sodium nitroprusside (David Bull Laboratories, Australia) at 2, 4 and 8 µg\min, each for 3 min, and then N G -monomethyl-L-arginine (Clinalfa, Switzerland) at 2, 4 and 8 µmol\min for 5 min each.
N G -Monomethyl-L-arginine (L-NMMA) was chosen because it is a stereospecific competitive antagonist to the enzymic synthesis of [NO and the vasoconstriction elicited provides an indirect bioassay for basal activity of the [NO dilator system. The doses were selected according to their ability to inhibit basal [NO production without circulating and altering central haemodynamics. Acetylcholine (ACh) is an endothelium-dependent vasodilator which exerts its effect, at least in part, by stimulation of endothelial production of [NO, whereas sodium nitroprusside (SNP) is an endothelium-independent vasodilator which donates [NO to directly relax vascular smooth muscle.
Treatment and analysis of data
Although the low doses of drugs infused in the study produced negligible systemic effects and showed no effect on blood pressure or heart rate, it is still desirable to exclude an alteration in overall haemodynamics as a cause of the flow changes seen in the infused forearm. These considerations, and the mode of expression of FBF to which they lead, have been recently reviewed [21] . Thus, FBF was measured simultaneously in both arms (although only one arm was infused), and the noninfused arm served as a control. As in other studies [20, 22] , FBF in the infused arm is described as a ratio to that in the non-infused arm. Changes in these ratios during ACh, SNP and L-NMMA infusions are expressed as percentage changes from the baseline immediately preceding each drug administration [21] . From previous studies, the coefficients of variation of changes induced by these drug infusions carried out twice, 4 weeks apart in the absence of other intervention, were 18 % for L-NMMA and cholinergic stimulation [20, 23] . In addition, vascular resistance was calculated in the infused arm by dividing mean arterial pressure by FBF and is expressed in the units mmHg per ml of 100 ml tissue\minute.
Drug responses were analysed using a commercially available statistics package (SAS Institute, Cary, NC, U.S.A.). Two-way analysis of variance with repeated measures was used to compare, at three levels of ACh, SNP and L-NMMA, the responses after vitamin E and placebo treatments. Other analyses involving comparisons between treatments were performed using Student's paired t-test. Significance is reported where P 0.05. Results are expressed as meanspS.E.M.
RESULTS

Subject characteristics
Plasma lipid levels, heart rate and blood pressure data are presented in Table 1 . With the exception of triacylglycerol concentration, which increased (P 0.05), plasma lipid levels were unaltered by vitamin E administration, as was blood pressure. Heart rate was increased after vitamin E administration (P 0.01). No changes were evident in haematological or biochemical variables (results not shown). Administration of vitamin E significantly increased its plasma concentration (34.6p1.8 to 86.9p9.6 µmol\l; P 0.001) and no subject reported adverse effects.
Forearm blood flow responses
The absolute measurements of FBF in the infused and non-infused limbs during intra-arterial administration of each drug are presented in Table 2 . Baseline FBF values preceding infusion of the drugs ACh, SNP and L-NMMA were not different, indicating adequate washout periods between drug infusions. Vitamin E administration significantly augmented both the increase in FBF response to ACh (P 0.01) and the decrease resulting from L-NMMA (P 0.05) in the infused limb, whereas no differences were evident in response to SNP. Analysis of vascular resistance data (Table 3) produced results which corresponded with those described above.
Figure 1 Forearm blood flow response to three doses of acetylcholine after placebo (#) or vitamin E () administration for 4 weeks
Forearm blood flow is expressed as the percentage change in the ratio of flow in the infused arm to that in the non-infused arm relative to the baseline period preceding the administration of ACh. Values are meanspS.E.M. ; *P 0.001. Table 4 Percentage changes from baseline in the forearm blood flow ratio induced by drug infusions, after vitamin E and placebo treatments Values are meanspS.E.M. ACh and L-NMMA responses were significantly augmented by vitamin E (P 0.001 and P 0.01 respectively ; two-way analysis of variance).
Placebo
Vitamin E Vitamin E administration significantly augmented responses to both ACh (P 0.05) and L-NMMA (P 0.01), but not SNP. As described in the Methods section, it is of some importance to analyse the data in terms of FBF ratios, that is the ratio of flow in the infused arm to that in the non-infused arm, and to express these relative to the Vitamin E, nitric oxide and hypercholesterolaemia Table 4 ) were significantly increased by vitamin E administration (P 0.001). Similarly, the response to L-NMMA ( Figure 2 , Table 4 ) was augmented (P 0.01). No change was evident in the response to SNP (Figure 3 , Table 4 ).
DISCUSSION
The principal finding of the present study is that basal and stimulated [NO-related endothelial function, determined using plethysmographic assessment of FBF responses to L-NMMA and ACh, was significantly improved after 4 weeks administration of vitamin E in subjects with mild hypercholesterolaemia and no other risk factors for vascular disease. These results were evident whether data were expressed in terms of changes in absolute FBF, forearm vascular resistance or FBF ratios, the latter being our preferred method. This improvement after only 4 weeks therapy further emphasizes that endothelial function can be rapidly enhanced using appropriate interventions including lipidlowering therapy in hypercholesterolaemia [22] . This study, however, is the first to demonstrate a beneficial effect of vitamin E on endothelial function in humans, although studies in rabbits [14, 15] have provided evidence of a beneficial effect. Previous human studies have reported that vitamin E administration, either alone [17] [18] [19] [20] or in combination with other therapy [16, 17] , did not influence endothelial function. Disparity with the present result may be attributed to several factors. In our previous study [20] the same regime of vitamin E administration as used here did not change the responses to L-NMMA or noradrenaline ; ACh was not studied. Those normal subjects were younger and normocholesterolaemic, with average total serum cholesterol 1.5-2.0 mmol\l lower. This difference in cholesterol concentration may be pertinent given that Street et al. [24] reported that higher levels of vitamin E were protective against the risk of myocardial infarction only among subjects with high levels of serum cholesterol, raising the possibility that vitamin E administration may not confer benefit in patients with high endogenous levels of vitamin E or those in whom serum cholesterol is low or normal. In the negative study of McDowell et al. [17] , patients were receiving lipid-lowering therapy with simvastatin. Since basal and stimulated [NO function are augmented by short-term simvastatin therapy in hypercholesterolaemia [22] , it is possible that those patients had preserved endothelial function on entry to the study, before administration of vitamin E in a dose half that of the present one. Other studies in patients with hypercholesterolaemia have also been negative. Elliott et al. [18] examined male post-myocardial infarction patients of similar age and total serum cholesterol concentration to those in our study, and administered similar daily doses of vitamin E for a period of 3 months. Although no effect of vitamin E on ACh responses was found, the heterogeneity of the patients, all of whom had risk factors for myocardial infarction and were being treated with drugs likely to improve endothelial function, would mitigate against finding a beneficial effect, especially if this effect was relatively specific to hypercholesterolaemia. In another recent study [19] , 400 i.u. of vitamin E administered daily for 8 weeks did not improve endothelial function in subjects with similar hypercholesterolaemia to ours, with angiographic coronary artery disease and various medications.
Vitamin E has been used in conjunction with other antioxidants. Vitamins E and C, β-carotene and zinc sulphate were found to decrease blood pressure in both normotensive and hypertensive subjects and the increase in urinary nitrite seen in the hypertensive subjects was taken as possible evidence for an increase in [NO-related dilator activity [25] . However, Gilligan et al. [16] gave 800 i.u. of vitamin E daily, along with β-carotene and vitamin C, to subjects with slightly higher serum cholesterol concentrations than ours and reported no effect on endothelial function studied by plethysmography. Vitamin C, under some circumstances, may act as a prooxidant due to generation of free radicals [26] [27] [28] [29] . In this context it may be relevant that, while vitamin E inhibits monocyte adhesion to human endothelial cells, vitamin C in one study stimulated adhesion and the combination of the two vitamins had no effect [12] . It is possible, therefore, that a beneficial effect of vitamin E in the study of Gilligan et al. [16] was moderated by concurrent vitamin C administration. On the other hand, acute administration of vitamin C alone, either orally or intraarterially, improves endothelial function in patients with diabetes [30] and coronary artery disease [31] . The interaction between antioxidant vitamins therefore appears complex and requires further elucidation.
Although the results of the present study do not reveal the mechanisms for an effect of vitamin E on endothelial function, several possibilities exist. Vitamin E-mediated decreases in the oxidation of LDL, most apparent at doses of 400 i.u. or more daily [6] , may protect endothelium-derived [NO function since oxidized LDL directly impairs [NO activity [32] [33] [34] . In the cholesterolfed rabbit, vitamin E decreased oxidation of LDL and preserved endothelial function [14] . Additionally, vitamin E may protect the endothelium more directly from damage by oxidized lipids, for example by inhibiting the activation of protein kinase C by oxidized LDL [13] . Protein kinase C can inhibit endothelial function by interfering with receptor-mediated stimulation of [NO production [35, 36] , endothelial cell [NO synthase activity [37, 38] or by increasing [O # − production [39] . Effects other than those on endothelial function might, of course, be relevant to a beneficial effect on atherogenesis [5, 11, 12] .
Account should be taken of a number of factors when interpreting this study. Only a small group of subjects was studied, but this was a prospective decision. The statistical significance and consistency of the results, and concordance between the two different endotheliumdependent drugs in contrast to those of the endotheliumindependent drug, are unlikely to have occurred by chance. As discussed above, an effect of vitamin E might depend critically upon the mechanism of endothelial dysfunction and could be relatively specific to that associated with hypercholesterolaemia. Indeed, that was the rationale for studying this select group but it warns against extrapolating the results to others. Furthermore, if hypercholesterolaemia is treated with lipid-lowering therapy, thereby improving endothelial function [22] , the additional value of vitamin E is likely to be questionable. The dose of vitamin E could be important since there is some evidence that the inhibition of oxidation of LDL is most apparent at 400 i.u. or more daily [6] ; the dose required to produce other effects and the optimal supplemental dose in the short or long term are unknown [5] . Another limitation is that the order of administration of vitamin E and placebo was not randomized since the high lipid solubility and consequent prolonged tissue half-life of vitamin E might have rendered the results from patients receiving vitamin E before placebo difficult to interpret. This is a common limitation in studies of antioxidant vitamins [16, 18] . It must be acknowledged that it remains unclear why vitamin E improved [NOrelated dilator function in this study while other studies have been negative. This could relate to the presence of mild hypercholesterolaemia in the absence of other risk factors or therapies, and to the dose and duration of vitamin E supplementation.
In conclusion, this study has established that, in patients with mild hypercholesterolaemia not receiving lipid-lowering or other prescribed medication, and in whom other known influences on endothelial function are absent, vitamin E administration can improve basal and stimulated function of the endothelium.
